Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.

Cancer science - 1 Sept 2010

Ji Hongbin

Abstract excerpt

Oncogenic mutation of epidermal growth factor receptor kinase domain is strongly associated with clinical response to tyrosine kinase inhibitors in non-small-cell lung carcinoma. Despite an initial encouraging response, patients eventually develop drug resistance and relapse. Great efforts have b...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to ErbB Receptors
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 20560975
DOI: 10.1111/j.1349-7006.2010.01629.x
PMCID: PMC11158733

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20560975-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.PMID 20560975Read ↗

Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.Semantic proximity Read ↗

Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities.Semantic proximity Read ↗

Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges.Semantic proximity Read ↗

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.Semantic proximity Read ↗

Pathological transition as the arising mechanism for drug resistance in lung cancerSemantic proximity Read ↗

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.Semantic proximity Read ↗

Overcoming therapy resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

The advanced research of immunotherapy in Epidermal growth factor receptor mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.Semantic proximity Read ↗

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.